Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| argenx SE | VYVGART - (ADAPT SERON) | Myasthenia Gravis | PDUFA | Ongoing | Intravenous | Neurology |
| argenx SE | ARGX-119 | Healthy volunteers, Muscle-specific kinase (MuSK) | BLA Filing | Ongoing | Intravenous | Neurology |
| argenx SE | Efgartigimod - (ALPHA) | COVID-19-mediated postural orthostatic tachycardia syndrome (POTS) | Phase 2 | Ongoing | Intravenous | COVID-19 |
| argenx SE | Empasiprubart (ARGX-117) - (EMPASSION) | Multifocal motor neuropathy (MMN) | Phase 3 | Ongoing | Intravenous | Neurology |
| argenx SE | Efgartigimod | Lupus nephritis | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| argenx SE | Empasiprubart (ARGX-117) - (EMPASSION) | Multifocal motor neuropathy (MMN) | Phase 3 | Ongoing | Intravenous | Neurology |
| argenx SE | Adimanebart | Congenital myasthenic syndromes (CMS) | Phase 3 | Trial Planned | Oral | Neurology |
| argenx SE | Efgartigimod - (UplighTED) | Thyroid eye disease (TED) | Phase 3 | Trial Discontinued | Intravenous | Opthalmic |
